Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (432)	12/6/2003 5:37:23 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BCRX Has had a good performance this year with a nice run from its January 29 L of 0.82 to its October 24 H of 9.41 (up bout 1,047% <g>) With the ASH meeting starting in San Diego, BCRX is expected to report on its PNP Inhibitor, BCX-1777 which has been shown to be able to modulate T-cell activities, for potential treatment of T-cell cancers, psoriasis and RA. I don't know if it will also present any information on its TF/FVIIa inhibitor, BCX-3607 which is under development for treatment of unstable angina. signonsandiego.com At any rate,it seem that BCRX has a good chance of testing its October 24 H of 9.41 this week.<g> siliconinvestor.com In spite of its trending tendency since late October, BCRX still has kept on its UPTREND bigcharts.marketwatch.com Bernard